Poractant alfa - Chiesi/Karolinska Institute
Alternative Names: CHF 1534; Curasurf; Curosurf; Curosurf LISA; Curosurf+catheter CHF6440; LISA combination productLatest Information Update: 20 Dec 2023
At a glance
- Originator Chiesi; Karolinska Institute
- Developer Chiesi; Dey Laboratories
- Class Phospholipids; Pulmonary surfactants
- Mechanism of Action Cell membrane permeability modulators; Surface active agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neonatal respiratory distress syndrome
- Phase II SARS-CoV-2 acute respiratory disease
Most Recent Events
- 25 Sep 2023 Cheisi terminates a phase I trial for Neonatal respiratory distress syndrome (following deep hypothermic circulatory arrest) (In infants, In neonates) in USA (NCT04181255)
- 22 Sep 2022 Chiesi terminates the phase III LISPAP trial in Neonatal respiratory distress syndrome in USA due to sponsor's decision (NCT02772081)
- 28 Mar 2022 Chiesi terminates a phase-II trial as enrolment has been extended 2 years in SARS-COV-2 acute respiratory disease in Italy, USA and UK (Endotracheal) (NCT04502433) (EudraCT2020-002632-75)